[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
Background Our understanding of the global scale of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data …
Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
[HTML][HTML] Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in …
ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B. 1.617. 2) variant surge in India: a test-negative, case-control study and …
R Thiruvengadam, A Awasthi, G Medigeshi… - The Lancet Infectious …, 2022 - thelancet.com
Background SARS-CoV-2 variants of concern (VOCs) have threatened COVID-19 vaccine
effectiveness. We aimed to assess the effectiveness of the ChAdOx1 nCoV-19 vaccine …
effectiveness. We aimed to assess the effectiveness of the ChAdOx1 nCoV-19 vaccine …
[HTML][HTML] Whole inactivated virus and protein-based COVID-19 vaccines
PJ Hotez, ME Bottazzi - Annual Review of Medicine, 2022 - annualreviews.org
The rapid development and deployment of mRNA and adenovirus-vectored vaccines
against coronavirus disease 2019 (COVID-19) continue to astound the global scientific …
against coronavirus disease 2019 (COVID-19) continue to astound the global scientific …
[HTML][HTML] Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
The Omicron variant of SARS-CoV-2 recently swept the globe and showed high level of
immune evasion. Here, we generate an Omicron-specific lipid nanoparticle (LNP) mRNA …
immune evasion. Here, we generate an Omicron-specific lipid nanoparticle (LNP) mRNA …
Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 …
NAN Hanafy, MA El-Kemary - International journal of biological …, 2022 - Elsevier
Respiratory infected by COVID-19 represents a major global health problem at moment
even after recovery from virus corona. Since, the lung lesions for infected patients are still …
even after recovery from virus corona. Since, the lung lesions for infected patients are still …
[HTML][HTML] Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label …
S Thuluva, V Paradkar, SR Gunneri, V Yerroju… - …, 2022 - thelancet.com
Background We assessed the efficacy of a receptor-binding domain (RBD)-based protein
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 …
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 …
[HTML][HTML] Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
B Lo Sasso, L Agnello, RV Giglio, CM Gambino… - Scientific Reports, 2022 - nature.com
Immunosurveillance by evaluating anti-spike protein receptor-binding domain (S-RBD)
antibodies represents a useful tool to estimate the long immunity against Severe Acute …
antibodies represents a useful tool to estimate the long immunity against Severe Acute …